HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist.

AbstractBACKGROUND:
Vitamin K antagonists are commonly used for the prevention of thromboembolic events. Patient self-monitoring of vitamin K antagonists has proved superior to usual care. Dabigatran has been shown, relative to warfarin, to reduce thromboembolic events without increasing bleeding.
METHODS:
We constructed a Markov model to compare vitamin K self-monitoring strategies to dabigatran including effectiveness and costs of monitoring and complications (thromboembolism and major bleeding). The model was used to project the incidence of these complications, life years, quality-adjusted life years, and health system costs with anticoagulant treatment throughout life. The analysis was conducted from the health system perspective and from the societal perspective.
RESULTS:
Low quality evidence suggests that self-monitoring is at least as effective as dabigatran for the outcomes of thrombosis, bleeding and death. Moderate quality evidence that patient self-monitoring is more effective than other forms of monitoring degree of anticoagulation with vitamin K antagonists, reducing the relative risk of thromboembolism by 41% and death by 34%. The cost per quality adjusted year gained relative to other warfarin monitoring strategies is well below 30,000 € in the short term, and is a dominant alternative from the fourth year. In comparison with dabigatran, the lower annual cost and its equivalence in terms of effectiveness made self-monitoring the dominant option. These results were confirmed in the probabilistic sensitivity analysis.
CONCLUSIONS:
We have moderate quality evidence that self-monitoring of vitamin K antagonists is a cost-effective alternative compared with hospital and primary care monitoring, and low quality evidence, compared with dabigatran. Our analyses contrast with the available cost analysis of dabigatran and usual care of anticoagulated patients.
AuthorsMisericòrdia Carles, Max Brosa, Juan Carlos Souto, Josep Maria Garcia-Alamino, Gordon Guyatt, Pablo Alonso-Coello
JournalBMC health services research (BMC Health Serv Res) Vol. 15 Pg. 289 (Jul 28 2015) ISSN: 1472-6963 [Electronic] England
PMID26215871 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anticoagulants
  • Antithrombins
  • Benzimidazoles
  • Fibrinolytic Agents
  • Vitamin K
  • Warfarin
  • Dabigatran
Topics
  • Anticoagulants (economics, therapeutic use)
  • Antithrombins (economics, therapeutic use)
  • Atrial Fibrillation (drug therapy)
  • Benzimidazoles
  • Cost-Benefit Analysis
  • Dabigatran (economics, therapeutic use)
  • Drug Monitoring
  • Fibrinolytic Agents
  • Hemorrhage (drug therapy, economics)
  • Humans
  • Male
  • Markov Chains
  • Quality-Adjusted Life Years
  • Self Care
  • Stroke (economics)
  • Thrombosis (prevention & control)
  • Vitamin K (antagonists & inhibitors)
  • Warfarin (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: